The insider sales are routine post-exercise diversification by non-executive directors and are immaterial relative to market cap. No C-suite selling or cross-filing red flags exist. Monitor for any C-suite open-market sales or a material increase in selling volume above 0.1% of market cap, which would warrant a more bearish read.
Price Chart
Executive Summary
Two BridgeBio directors executed open-market sales totaling $11.56M on July 9, 2026, following derivative exercises. Director Cook sold $10.12M at $90/share and Director Ellis sold $1.44M at $84/share. The sales represent ~0.07% of the $16.3B market cap, falling below the 0.1% materiality threshold, and are consistent with routine post-exercise diversification. No C-suite executives participated, and the cluster is not amplified by any cross-filing context that would suggest informed selling.
Key Financial Metrics
Key Facts
- Two directors (Cook and Ellis) sold a combined $11.56M in open-market transactions on July 9, 2026
- Director Cook sold 112,422 shares at $90/share ($10.12M) and 36,167 shares at $84/share ($3.04M)
- Director Ellis sold 17,167 shares at $84/share ($1.44M)
- All sales followed derivative exercises at prices between $0 and $29/share, generating non-cash gains
- Total open-market sales represent ~0.07% of BridgeBio's $16.3B market cap
- No C-suite executives (CEO, CFO, COO) participated in the cluster
- No 10b5-1 plan designation was noted in the filings
- The cluster is not accompanied by any earnings, restructuring, or late-filing context that would amplify its significance
Financial Impact
Total open-market sales of $11.56M, representing ~0.07% of market cap — below the 0.1% materiality threshold for insider clusters
Risk Factors
- Insider selling could accelerate if the stock continues to appreciate, but current levels are not alarming
- Derivative exercises add to public float, though the ~149K shares exercised are negligible for a $16.3B company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1784009308941 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access